Citations

Clear

9383 citation(s) found for "Thomas, PS".

Cardiovascular Health in Cardiac Rehabilitation: Applying the American Heart Association Life's Simple 7 Framework in a Center‐Based Cohort
Chacin‐Suarez, Audry , Hama, Tomoaki , Johnson, Matthew P. , Abraham, Helayna , Olson, Thomas P. , Brewer, LaPrincess C. , Brewer, LaPrincess C , Chacin Suarez, Audry S

Mayo Clinic

Journal of the American Heart Association | June 5, 2025 | Volume: 14 | Issue: 12 | Pages: No page available

10.1161/jaha.124.039010 | PMID 40470642 Get It

Background Cardiac rehabilitation (CR) is a comprehensive secondary cardiovascular disease program with structured lifestyle interventions to reduce morbidity and mortality. The American Heart Association cardiovascular health (CVH) framework measures health‐promoting behaviors and clinical factors, but it has not been rigorously evaluated in the CR setting. Methods This retrospective cohort study analyzed patients attending CR from January 2018 to September 2020. Patients were evaluated at baseline (pre‐CR) and completion (post‐CR) using 3 clinical factors (blood pressure, cholesterol, and hemoglobin A1c) and 4 health behaviors (smoking, body mass index, physical activity, and diet). CVH score was computed as a composite of each Life's Simple 7 component by assigning 0 points for poor, 1 point for intermediate, or 2 points for ideal (range 0–14 points). CVH scores were further categorized as poor (0–6 points), intermediate (7–8 points), and ideal (9–14 points). Missing data in the analysis were accounted for using a multiple imputation procedure. Results Patients (N=937) were aged 64.0±13.4 years old, 34% women, and attended 11±12 CR sessions. Pre‐CR, 97.2% had poor CVH scores, 2.8% had intermediate scores, and none met ideal CVH criteria. Post‐CR, there was a reduction in poor scores across all metrics except for hemoglobin A1c, which increased (40.6%–43.5%). Younger patients showed improvement in hemoglobin A1c, while older patients improved in body mass index and blood pressure. Conclusions Our study demonstrates the efficacy of CR in improving CVH but underscores the need for better blood glucose management. Tailored interventions based on age and sex may further optimize outcomes for CR participants.
A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint
Vega, Rodolfo E. De la , Sellon, Jacob L. , Smith, Jay , Wisniewski, Stephen, Jurisson, Mary L. , Frick, Matthew A., Scrabeck, Tyson L., Block, Julie B., Mills, Candee J. , Pohlkamp, Zachary W., Coenen, Michael J., Hawse, Gresin P. , Abdul, Temilola Y. , Conaghan, Philip G. , Keravala, Annahita, Robbins, Paul D. , Ghivizzani, Steven C. , Evans, Christopher H. , De La Vega, Rodolfo E , Wisniewski, Stephen J, Conaghan, Philip , Chalberg, Thomas W , Robbins, Paul D , Ghivizzani, Steven C , Evans, Christopher H , Block, Julie B.

Mayo Clinic

Science Translational Medicine | June 4, 2025 | Volume: 17 | Issue: 801 | Pages: No page available

10.1126/scitranslmed.adu9804 | PMID 40465688 Get It

Osteoarthritis (OA) is a major global health problem with no disease-modifying therapies. Interleukin-1 (IL-1) is a critical cytokine associated with the pathophysiology of OA and can be inhibited by IL-1 receptor antagonist (IL-1Ra). Here, we tested the delivery of a gene therapeutic encoding the human IL-1Ra to the knee in a phase 1, open-label clinical trial that enrolled nine patients with radiographic knee OA. The IL-1Ra gene was delivered by a self-complementary (sc)–recombinant adeno-associated virus (rAAV) serotype 2.5 (sc-rAAV2.5IL-1Ra) by intra-articular injection into an index knee at one of three doses: low [1 × 10 11 viral genomes (vg)], mid (1 × 10 12 vg), or high (1 × 10 13 vg). The primary outcome was safety. There were no serious adverse events (AEs) related to sc-rAAV2.5IL-1Ra. Two AEs occurred that were possibly related to the vector. Both were effusions with increased pain and resolved with conservative treatment. sc-rAAV2.5IL-1Ra did not cause changes in vital signs, physical findings, or clinical laboratory measures. Less than 1% of the injected dose of sc-rAAV2.5IL-1Ra vg was detected in circulation after 1 day and was cleared within a week. Titers of neutralizing antibodies to AAV2.5 rose in serum and synovial fluid. In all cases, IL-1Ra concentration increased in the synovial fluid, and IL-1Ra concentrations remained elevated after 1 year. Baseline pain and function scores improved during the study. Therefore, we found that intra-articular gene therapy with sc-rAAV2.5IL-1Ra was safe. The sustained increase in local IL-1Ra in human knee joints supports the further clinical examination of this therapy to provide therapeutic benefit in OA.
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).
Picozzi, Vincent J. , Chandana, Sreenivasa R , Kasi, Anup , Jin, Gang , Bullock, Andrea J. , Chunyi, Hao, Osipov, Arsen , Lee, Woo Jin , Feeney, Kynan, Ueno, Makoto , Seufferlein, Thomas , Investigators, PANOVA-3 Study, Babiker, Hani M. , Melichar, Bohuslav , Gállego, Javier , Wyrwicz, Lucjan , Fouchardière, Christelle de la , Dragovich, Tomislav , Philip, Philip A. , Cutsem, Eric Van , Macarulla, Teresa , Investigators, PANOVA-3 Study

Mayo Clinic

Journal of Clinical Oncology | June 4, 2025 | Volume: 43 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2025.43.17_suppl.lba4005 Get It

LBA4005 Background: To date, no phase 3 clinical trial has demonstrated an overall survival (OS) benefit in patients with locally advanced pancreatic adenocarcinoma (LA-PAC). TTFields are electric fields that disrupt cancer cell division. TTFields therapy is approved for glioblastoma, pleural mesothelioma, and metastatic non-small cell lung cancer. A phase 2 trial in PAC demonstrated the safety and preliminary efficacy of TTFields therapy with gemcitabine with or without nab-paclitaxel. We report final data from PANOVA-3 (NCT03377491), the largest global, phase 3, randomized, open-label trial in LA-PAC to date. Methods: Adult patients with newly diagnosed unresectable LA-PAC were randomized 1:1 to receive TTFields therapy (150 kHz) with gemcitabine/nab-paclitaxel (GnP) or GnP. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), local PFS, objective response rate (ORR), and pain-free survival. Distant PFS (metastases beyond the pancreas and regional lymph nodes) was assessed post hoc. Survival data were compared using the Kaplan-Meier method and a log-rank test. Results: 571 patients were randomized. Baseline characteristics were generally well balanced between the study arms. OS was significantly longer with TTFields/GnP than with GnP (median 16.2 [95% CI: 15.0, 18.0] vs 14.2 months [95% CI: 12.8, 15.4]; HR 0.82 [95% CI: 0.68, 0.99], p=0.039). One-year survival rate was also significantly improved with TTFields/GnP vs GnP (68.1% [95% CI: 62.0-73.5] vs 60.2% [95% CI: 54.2-65.7], p=0.029). There was no significant difference in PFS or local PFS between arms. Pain-free survival was significantly longer with TTFields/GnP vs GnP (median 15.2 [95% CI: 10.3, 22.8] vs 9.1 months [95% CI: 7.4, 12.7]; HR 0.74 [95% CI: 0.56, 0.97], p=0.027). Post-hoc analysis showed significant distant PFS benefit (median 13.9 [95% CI: 12.2, 16.8] vs 11.5 months [95% CI: 10.4, 12.9], HR 0.74 [95% CI: 0.57, 0.96], p=0.022) with TTFields/GnP vs GnP. ORR was similar between arms (36.1% [95% CI: 30.0, 42.4] vs 30.0% [95% CI: 24.3, 36.2], p=0.094). 97.8% and 98.9% of patients who received TTFields/GnP and GnP, respectively, had adverse events (AEs) and 88.6% and 84.3% had grade ≥3 AEs. The most frequent grade ≥3 AEs were neutropenia (47.8% and 47.6%) and anemia (21.9% and 22.3). 81% of patients receiving TTFields/GnP had device-related AEs, mostly grade 1/2 skin AEs, e.g., dermatitis (27.7%), rash (17.5%), and pruritus (15.0%); grade 3 and grade 4 device-related AEs occurred in 9.1% and 0.4% of patients, respectively. Conclusions: PANOVA-3 is the largest phase 3 trial exclusively performed in patients with LA-PAC and the first to show a statistically significant OS benefit. With no additive systemic toxicity and a statistically significant pain-free survival benefit, TTFields therapy is a potential new standard treatment for LA-PAC. Clinical trial information: NCT03377491 .
Refractory Diarrhea Related to EPHB4 Mutation in a Patient With Capillary Malformation-Arteriovenous Type 2 Syndrome
McNally, Bridgette B. , Liu, Margaret C., Horsley‐Silva, Jennifer L. , Swanson, Karen L., Byrne, Thomas , Smith, Maxwell, Lunsford, Tisha , Horsley-Silva, Jennifer, Swanson, Karen, Salomao, Marcela , Frazier, Rosita

Mayo Clinic

ACG Case Reports Journal | June 4, 2025 | Volume: 12 | Issue: 6 | Pages: e01707

10.14309/crj.0000000000001707 | PMID 40469463 Get It

ABSTRACT Capillary malformation-arteriovenous type 2 syndrome (CM-AVM2) is a rare, genetic vascular disorder associated with abnormal capillary malformations and arteriovenous malformations. We present a case of CM-AVM2 with refractory diarrhea and failure to thrive due to aberrant, telangiectatic capillaries, and subepithelial collagen deposition found throughout the GI tract on bidirectional endoscopy. The patient was recalcitrant to standard therapies, so bevacizumab was trialed, but the patient expired. This is the first case of CM-AVM2 with diffuse GI mucosal involvement resulting in malabsorption. There is no treatment for this pathology, but treatment with bevacizumab or a mammalian target of rapamycin inhibitor may be efficacious.
Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi, Shadi, Shu, Liqi , Mandel, Daniel , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Seiffge, David , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Mena, Diego López, Araúz, Antonio , Nehme, Ahmad , Boulanger, Marion , Sousa, João André , Sargento‐Freitas, João , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Kaufmann, Josefin E. , Engelter, Stefan T. , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Metanis, Issa , Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , MacDonald, Jason , Shahripour, Reza Bavarsad , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim, Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Giles, James , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Chulluncuy‐Rivas, Roberto, Aziz, Yasmin , Bakradze, Ekaterina , Tran, Thanh Lam , Rodrigo‐Gisbert, Marc , Velez, Faddi Saleh, Gracia, Jorge Ortiz, Mudassani, Varsha, Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Ranasinghe, Tamra , Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel, Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Lingam, Sivani, Quereshi, Abid, Alvarado, Alonso, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris, Vasilis, Martínez-Marino, Manuel , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Kala, Narendra , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Alvarado‐Bolaños, Alonso , Tentolouris-Piperas, Vasileios , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Liebeskind, David S. , Field, Thalia S , Keser, Zafer , Aziz, Yasmin , Mandel, Daniel M , Seiffge, David , Arauz, Antonio , Sousa, Joao Andre , Sargento-Freitas, Joao , Castro-Chaves, Paulo , Kaufman, Josefin E , Engelter, Stefan T , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Nolte, Christian H , Bavarsad Shahripour, Reza , Almajali, Mohammad , Fonseca, Ana Catarina , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Nzwalo, Hipolito , Mac Grory, Brian , Eltatawy, Ali , Rodrigo Gisbert, Marc , Vishnu, Venugopalan Y , Ranasinghe, Tamra , Mendes Ferreira, Vítor , Kim, Young Dae , Elangovan, Cheran , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Ghani, Mohammad , Xiao, Han , Khan, Farhan , Nehme, Ahmad , Yaghi, Shadi , Antonenko, Kateryna , Arnold, Marcel , Touzé, Emmanuel , Leker, Ronen R , Burton, Tina , von Rennenberg, Regina , MacDonald, Jason, Guo, Xiaofan , Samaniego, Edgar A , Rioux, Bastien , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Zedde, Marialuisa , Pascarella, Rosario , Anadani, Mohammad , Kicielinski, Kimberly , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Siegler, James E. , Willey, Joshua , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Martins, Sheila , Fridman, Sebastian , Liu, Shilin , Ali, Farman, Morsi, Rami Z. , Sokhi, Dilraj , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Stretz, Christoph , Goldstein, Eric

Mayo Clinic

Stroke | June 4, 2025 | Volume: 55 | Issue: 4 | Pages: 908-918

10.1161/strokeaha.123.045731 | PMID 38335240 Get It

BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45–1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28–2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35–5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53–20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18–0.88]; P interaction =0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)
Chabrun, Floris , Schwartz, Daniel L. , Gentile, Susanna, Elias, K. , Gupta, Tulika , Perry, Jacqueline , Santos, David M. Cordas dos , Hielscher, Thomas , Werly, Annika, Schmidt, Sophia, Liacos, Christine‐Ivy , Kanellias, Nikolaos , Gisbert, Noelia Collado, Chavda, Selina J , Ainley, Louise , Magistris, Claudio De, Pettine, Loredana , Timonian, Michael , Tobia, Catherine, Phan, Sally, Lamb, Jennifer, Silverio, Maria-Theresa, O’Donnell, Elizabeth , Mateos, María‐Victoria , Kumar, Shaji , Kastritis, Efstathis, Trippa, Lorenzo , Mai, Elias K , Santos, David Cordas Dos , Timonian, Michael , Alberge, Jean-Baptiste , Bolli, Niccolo' , Yong, Kwee , Kortüm, Martin , Einsele, Hermann , Mateos, María-Victoria , Kumar, Shaji K , San-Miguel, Jesus , Paiva, Bruno , Dimopoulos, Meletios A , Raab, Marc S , Ghobrial, Irene M , Schwartz, Daniel S. , Gentile, Susanna , Gupta, Tulika R. , Perry, Jacqueline, Schmidt, Sophia K., Theodorakakou, Foteini , Fotiou, Despina , Liacos, Christine Ivy, Martín‐Sánchez, Esperanza , Termini, Rosalinda , Waldschmidt, Johannes M , Ainley, Louise, Vià, Matteo Da , Alberge, Jean-Baptiste , Patel, Vidhi, Costello, Patrick , Tobia, Catherine, Phan, Sally, Lamb, Jennifer, Silverio, Maria-Theresa, Davis, Maya, Marinac, Catherine R. , Nadeem, Omar , Bolli, Niccolò , Yong, Kwee , Kortüm, K. Martin , Miguel, Jesús F. San , Paiva, Bruno , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Raab, Marc S. , Ghobrial, Irene M.

Mayo Clinic

No container title available | June 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6696313/v1 | PMID 40502745 Get It

Abstract Accurate prediction of risk of progression from smoldering (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not account for evolving biomarker trajectories. We assembled the largest cohort to date of 2,270 SMM patients from six international centers with longitudinal clinical and biological data to train and validate the PANGEA 2.0 risk models. Four evolving biomarkers were significantly associated with shorter time-to-progression: M-protein increase ≥0.2g/dL, involved:uninvolved serum free light chain ratio increase ≥20, creatinine increase >25%, and hemoglobin decrease ≥1.5g/dL. PANGEA 2.0 outperforms established models including the 20/2/20 and IMWG models by more accurately predicting progression (C-statistics=0.69–0.84), even without biomarker history (C-statistics=0.69–0.83) or recent bone marrow biopsy. PANGEA 2.0 is an easy-to-use, open-access tool (https://ghobrial.shinyapps.io/pangea_2_calculator) to improve and individualize SMM risk stratification. Validation tools are available to compare PANGEA 2.0 to established models (https://ghobrial.shinyapps.io/pangea_validation).
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Jagannath, Sundar , Martin, Thomas G. , Lin, Yi , Cohen, Adam D. , Raje, Noopur , Htut, Myo, Deol, Abhinav , Agha, Mounzer , Berdeja, Jesús G. , Liegel, Jessica J., Dhakal, Binod , Parekh, Samir , de, Rocío Montes , Plaks, Vicki , Sun, Huabin, Banerjee, Arnob , Schecter, Jordan M. , Lendvai, Nikoletta , Lengil, Tamar, Zhu, Jieqing, Koneru, Mythili, Akram, Muhammad, Patel, Nitin , Filho, Octavio Costa, Voorhees, Peter M. , Liegel, Jessica J , Rossi, Adriana , Lieberman-Cribbin, Alex , Usmani, Saad , Dhakal, Binod , Parekh, Samir , Montes de Oca, Rocio , Jakubowiak, Andrzej , Voorhees, Peter , Cohen, Adam D , Jagannath, Sundar , Lin, Yi , Berdeja, Jesús G , Raje, Noopur S , Htut, Myo , Lesokhin, Alexander M. , Rossi, Adriana , Usmani, Saad Z. , Li, Hui, Wang, Rui , Madduri, Deepu , Jakubowiak, Andrzej

Mayo Clinic

Journal of Clinical Oncology | June 3, 2025 | Volume: 43 | Issue: 25 | Pages: 2766-2771

10.1200/jco-25-00760 | PMID 40459151 Get It

CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32/97) of patients remain alive and progression-free for ≥5 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10 −5 threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for ≥5 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of naïve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with ≥5-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Babiker, Hani M. , Picozzi, Vincent J. , Chandana, Sreenivasa R , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gállego, Javier , Bullock, Andrea J. , Chunyi, Hao, Hitre, Erika, Osipov, Arsen , Alés, Inmaculada, Dragovich, Tomislav, Lee, Woo Jin , Feeney, Kynan, Ueno, Makoto , Seufferlein, Thomas , Investigators, on behalf of the PANOVA-3 Study, Osipov, Arsen, Matrana, Marc , Blondin, Nicholas, Shroff, Rachna T. , Orr, Douglas, Anderson, Michael J. , Shields, Anthony F. , Hamm, John , Bullock, Andrea, Nagireddy, Sumana, Kolodney, Joanna, Dragovich, Tomislav, Maniam, Ajit, Sears, Judith D., Stilwill, Joseph, Cusnir, Mike , Niewiaroska, Anna, Small, William, Kasi, Anup, Tache, Jason, Ross, Sharona, Shihabi, Samer, Gandhi, Sunil, Reeves, J. N. , Green, Garrett , Feinstein, Trevor, Huyck, Timothy K., Ramdin, Nadia, Marsh, Robert , Jiang, Yixing , Hatoum, Hassan , Manda, Sudhir, Kochenderfer, Mark D., Illum, Henrik, Richards, Donald , Valilis, P., Wong, Lucas, Newton, Herbert B. , Abdelrahim, Maen, Einspahr, David, Siegel, Richard, McKenney, Scott, Narang, Mohit , Cárdenes, Higinia R. , Thanikachalam, Kannan , Raff, Joshua P. , Ye, Joseph , Behl, Deepti , Kam, Audrey E., DeRose, Paul, Tasneem, A. , Brenner, Warren, Santos, Jennifer De Los , Rausch, D C, Trikha, Gaurav, Gabrail, Nashat , Mowat, Rex B., Jahangir, Khawaja, Schumaker, Robert P. , Soffen, Edward , Bravin, Eric, Gupta, Mukul Kumar , Bedoya-Apraez, Ivan Dario, Kang, Tyler Y., Lemay, Frédéric , Vincent, Mark , Létourneau, Richard, Doehring, Christine, Haberkorn, Mike, Rußwurm, Karen, Chater, Jack, Küng, Marc , Schacher, Sabine, Passhak, Maria , Geva, Ravit , Hubert, Ayala, Golan, Talia , Senellart, Hélène, Trouilloud, Isabelle , Blan, Jean-Frederic, Dourthe, Luis-Marie, Roy, Florence Le, Martin-Babau, J., Greil, Richard , Schreil, Georg, Gerger, Armin , Eisterer, Wolfgang , Mercadé, T. Macarulla, Cubillo, Antonio , Pons, Francesc Valladares, Díaz, Inmaculada Alés, Rivera, Fernando , Sarvise, Mariano Ponz, Airoldi, Mario , Bellotti, Giovanna, Corsi, Domenico , Antonuzzo, Lorenzo , Melichar, Bohuslav, Holečková, Petra , Kotasek, Rostislav, Němeček, Radim , Cutsem, Eric van, Laethem, Jean‐Luc Van , Sym, Sun Jin , Kim, Jin Young , Oh, Sang Cheul , Park, Joon Oh, Kim, Jin Won , Lee, Myung Ah , Choi, Hye Jin, Kang, Seok Yun , Mruk, Andrzej, Freier, Beata, Kosakowska, Ewa Anna, Kocsis, Judit, Csőszi, Tibor , Hitre, Erika, Al-Farhat, Yousuf, Cang, Shundong , Jin, Gang , Zuo, Changzeng, Song, Lijie, Wu, Zheng , Gao, Jie , Zhang, Tao� , Wang, Yusheng , Yuan, Xin , Li, Zhi-Hua , Chen, Rufu , Cai, Xiujun , Zhu, Zhizhen, Bai, Yuxian , Bai, Chunmei, Yau, Thomas, Joubert, Warren , Wong, Ka Yeung Mark, Harris, Marion , Mišir, Ana, Faccio, Adilson , Cruz, Felipe Melo , Azevedo, Srergio De, Victorino, Ana Paula , Paiva, Tadeu Ferreira, Franke, Fábio , Tiscoski, Katsuki Arima , Parolla, Gabriel, Lilno, Flora, Siqueira, Mariana Bruno , Lyra, Marcos, Lira, Jose Luis Martinez, Oliva, Dolores Mendoza, Vazquez, Arturo, Luviano, Jesus Elvis Cabrera, Gutiérrez, Erika Castillo , Camargo, Vanessa Rosas, Guerra, Cristian Chavez, Flores, Osvaldo Hernandez, Contreras, Jessica Reyes, Villanueva, Ángel Gómez, Villanueva, Omar Zayas, Bullock, Andrea , Wyrwicz, Lucjan , Osipov, Arsen , De La Fouchardiere, Christelle , Lee, Woojin , Ueno, Makoto , Van Cutsem, Eric , Macarulla, Teresa , Babiker, Hani , Antonuzzo, Lorenzo , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gallego, Javier , Hitre, Erika, Fouchardière, Christelle de la , Dragovich, Tomislav, Philip, Philip A. , Cutsem, Eric Van , Macarulla, Teresa , Investigators, on behalf of the PANOVA-3 Study, Spigel, David R. , Osipov, Arsen, Lou, Emil , Bullock, Andrea, Dragovich, Tomislav, Coveler, Andrew L. , Arena, Francis P. , Kasi, Anup, Ross, Sharona , Reeves, James, Green, Garrett, Uemura, Marc Isamu , Ye, Joseph, Wang, James Z. , Rausch, Daniel, Park, Jae‐Hyun , Schumaker, Robert, Gupta, Mukul, Letourneau, Richard, Fuchs, Martin , Vogel, Arndt , Chater, Jack, Schacher, Sabine, Stemmer, Salomon M. , Dourthe, Luis-Marie, Abdelghani, Méher Ben , Pons, Francesc Valladares, Guillén‐Ponce, Carmen , Yayá, Ricardo , Ponz‐Sarvisé, Mariano , Vincenzi, Bruno , Melichar, Bohuslav, Petruzelka, Lubos B. , Cutsem, Eric van, Borbath, Ivan , Hwang, Jun‐Eul , Oh, Sung Yong , Lee, Moon Hee , Choi, Hye Jin , Chon, Hong Jae , Ramlau, Rodryg , Mruk, Andrzej, Hitre, Erika, Bassam, Ali, Hao, Chunyi , Liang, Bo , Li, Wei , Bai, Chunmei , Joubert, Warren, Marx, Gavin M. , Azevedo, Srergio De, Hoff, Paulo M. , Vazquez, Arturo, Guerra, Cristian Chavez, Cortez, David Orta, Campos-Gómez, Saúl , Espinoza, Iván Romarico González

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2350-2360

10.1200/jco-25-00746 | PMID 40448572 Get It

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC). METHODS In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle with or without TTFields. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR). Distant PFS was analyzed post hoc. RESULTS OS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0] v 14.2 months [95% CI, 12.8 to 15.4]; hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.99]; P = .039). PFS, local PFS, and ORR were not improved. Pain-free survival was significantly prolonged with TTFields with gemcitabine/nab-paclitaxel (median, 15.2 months [95% CI, 10.3 to 22.8] v 9.1 months [95% CI, 7.4 to 12.7]; HR, 0.74 [95% CI, 0.56 to 0.97]; P = .027), as was distant PFS (median, 13.9 months [95% CI, 12.2 to 16.8] v 11.5 months [95% CI, 10.4 to 12.9]; HR, 0.74 [95% CI, 0.57 to 0.96]; P = .022). Device-related skin adverse events (AEs) were experienced by 76.3% of patients. Most device-related skin AEs were mild to moderate, with 7.7% of patients reporting a grade 3 AE. CONCLUSION This study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.